Post-earnings recap
Reported
Mon, May 13, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report reflects ongoing challenges for Soleno Therapeutics, particularly with their EPS figures. The lack of revenue data and guidance may raise concerns among investors. The stock's decline of 1.62% indicates a cautious market reaction to the uncertainties presented in the call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to future projects and maintaining operational focus.
Management did not provide specific revenue figures for the quarter.
The company remains focused on its long-term goals despite current challenges.